Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Easton already made an investment into AMFIL. Press release states that they are entering into negotiations for additional investment. Considering that AMFIL has 7+ million dollars in sales I would say that's a good press release.
The press release also says they now have 4 acquisitions or investment negotiations that they are undergoing. I would say it's a good chance they're going to close on at least one of them.
Falinski is providing everyone with great posts and valuable information as is McKinkey. I am also frustrated with the delays with iBliss. Accounting issues caused delays. But Evan Karras will get this done. He is working on everyone's behalf. This company will soon demonstrate it and we won't be hearing from any trolls soon enough
They closed Gedeon Richter who put their name beside Easton, they will close with iBliss , a major JV with MMJ in Jamaica and they will close with Gedeon for AL-Sense. After that expect an announcement with Bayer for VS-Sense
Easton doesn't need an audit just like MJNA doesn't need one.
Easton has positive news to come out within days and not weeks. Nothing ever happens just like that with any company negotiating with large multinational's. Especially in the pharmaceutical industry. But any shareholder who doesn't want to wait could easily by Pfizer or some other company and if they're lucky they will make 20% in the next couple of years instead of 20% within an hour once a press release comes out. Where else can you go to make 20 or maybe 50 or maybe 2000% within a week or couple of weeks. If Easton closes on everything they are negotiating on, it could possibly reach $.15-$.30 cents.
I believe that Evan Karras wants to time these press releases so that there is one closing after the other and make an announcement consisting of one or two closing agreements per week. But I personally believe it's best to announce one per week and not two
The anticipated Jamaica closing is going to be a great venture for almost immediate revenues which will involve iBliss and their laboratories. Everyone will love what this brings Easton and shareholders
IBliss will close. They closed Gedeon Richter who put their name beside Easton, they will close with iBliss, a major JV with MMJ in Jamaica and they will close with Gedeon for AL-Sense. After that expect an announcement with Bayer for VS-Sense
After iBliss closes they have big MMJ news to announce.
It will close. One of the directors of iBliss was not available last week within 1 week means no later than Wednesday.
Easton products can be purchased in Mexico and Latin America. But they are looking into selling "Gynofit " in North America once its FDA approved. What a smart person should do is read press releases and financial statements. Then a reasonably intelligent person would know that "Gynofit " is selling in Mexico and Latin America. It's being sold through Gedeon Richter, a multi-billion dollar Pharma company. A PO has been paid for as announced for a soft launch. Sales have started but it takes time to get it into drug stores and ramp sales and distribution etc. they have a 3 year plan to ramp up sales.
Multi-billion dollar Pharma Company's don't invest $1,000,000 for marketing unless it will generate $10,000,000 or more.
The iBliss acquisition will be a transfer of a few million dollars in revenue to Easton.
Easton products can be purchased in Mexico and Latin America. But they are looking into selling "Gynofit " in North America once its FDA approved. What a smart person should do is read press releases and financial statements. Then a reasonably intelligent person would know that "Gynofit " is selling in Mexico and Latin America. It's being sold through Gedeon Richter, a multi-billion dollar Pharma company. A PO has been paid for as announced for a soft launch. Sales have started but it takes time to get it into drug stores etc. they have a 3 year plan to ramp up sales.
Multi-billion dollar Pharma Company's don't invest $1,000,000 for marketing unless it will generate $10,000,000 plus.
Report TOS
EAPH Easton Pharmaceuticals is one to put on your radar as something significant with MMJ could soon come
Easton or EAPH are days away from major announcements. How do I know this you ask. Because Easton has stated this on press releases and tweets. Read the press releases and see what's coming.
They already closed on Gynofit with multi-national Gedeon Richter which demonstrated that they have the right people working for them.
They now have AL-Sense and VS-Sense that are close to deals with Bayer and Gedeon.
Those are facts.
Easton is focusing on woman's diagnostics and treatment products, medical marijuana, a cancer drug that they are now refocused their energies and should be announced soon enough and other things not yet disclosed. But it's obvious that their over the counter products is not a big focus when you have Bayer, Gedeon Richter and any other large Company's that Easton is trying to do a deal with. If Eastin closes on half of what they are working on then EAPH could be a $.30 stock in the foreseeable future.
I think I can probably predict with a lot of confidence that you won't see these prices at this level for very much longer. I think there's going to be a slew of closing agreements that are going to be announced one after the other.
It will be iBliss, Gedeon Richter for AL-Sense, Bayer for VS-Sense, Jamaica MMJ. The future is looking good. New highs coming soon.
Bayer is definitely the word. So is Royalties.
I no longer care if it goes up or down by 10% or so. It's looking more more like they may have a slew of closing agreements to announce one after the other. New highs I believe are soon at hand.
Just saw a tweet from Easton. Sounds like they might be very close to a second deal involving MMJ in Jamaica. That would be a perfect fit with iBliss. It's obvious that they are trying to move this company forward with some of the cash they raised.
The buy in is confirmed. Why do you think the stock has gone up and down on several occasions. The same investment club that is made money 4 previous times will soon be at it again. Expect $0.06 cents shortly
EAPH is ready to rumble. I found out that there is an investment club whose name I will not mention who have with them 2500 members that are put Easton on their radar and on the buy list. Expect to see movement in the stock within the coming days as they see a double as they have played Easton four times in the last six months. I on one hand I don't want them to come in and buy the stock because those people sell it after they make 80 to 100% return. Easton needs long-term holders and not short term. But it does mean that the stock will have good movement very shortly. As I said before, you won't be seen at that this level for much longer.
Evan Karras is the right guy for this job. He's a self-made millionnaire in real estate and other business projects who is bringing in new people into Easton and new revenue generating businesses for a positive future.
News might go out by noon but management believes and has learned that it's best to get press releases out early in the morning at 6:00am. This is something that shareholders have told them which I'm glad they are listening to. I have found Evan Karras to be very open-minded to listening to new ideas and any shareholder concerns. When I spoke to him last I found him to be very intelligent and very pleasant.
Multibillion dollar pharmaceutical companies do not spend hundreds of thousands or millions of dollars in marketing to launch a new product such as Gynofit to only make a few hundred thousand dollars in profit.
Gedeon Richter now wants AL – Sense
Bayer wants VS – Sense
IBliss is already making profits with 40% profit margin's. I am confident that Evan Karras will get it closed this week. It will not dry gone past this week.
This is just the calm before the storm. The company will be back on track for 20 million shares a day plus in the next few days
Easton stock will go up on the announcement of the closing. But over time it will continue to go up as this is the long term hold.
If Easton closes on half of what they're negotiating on right now, this will be a $.30 stock
Easton paid cold hard cash for licensing of patented products. That shows that this company is trying to build a company with solid growth potential. You have to respect that.
I've been wrong before by listening to people who talk to Karras. But for the most part Easton indicates what they are doing on tweets and press releases. They don't deliver on everything but they never lie. Their credibility went way up when they delivered on sales through Gedeon Richter.
Easton was planning to get a press release out about iBliss and the company along with quotes from the CEO on Monday morning regarding the closing, but they decided to hold off because they are just a day or 2 from closing. A final agreement has been sent to Hung Tran at iBliss and it could actually close on Monday or Tuesday of this week.
Easton has closed with a multi-billion dollar pharmaceutical company to launch a product in the country with 150 million people. They will soon start sales in central America with another reputable company called Windsor pharmaceuticals. Anyone who can't see from these transactions that they have the ability to make deals with big companies is an idiot. That's why those people missed out on making or turning a $10,000 investment in September to $300,000 now.
If Easton closes on half of what they are in negotiations for, Easton is easily a $.15 stock.
MULTI-BILLION DOLLAR PHARMA COMPANYS SUCH AS GEDEON RICHTER DO NOT LAUNCH PRODUCTS TO MAKE A FEW HUNDRED THOUSAND DOLLARS. THEY WANT MILLIONS IN SALES. WHO BENEFITS BUT EASTON. SALES LAUNCHED 2 WEEKS AGO
Easton's sales have started as they were delivered on the second payment of product by Gedeon Richter for the Gynofit PO.
A deal is on the table from Bayer for VS-Sense which is a product that Bayer is selling in Brazil and Europe.
A deal is on the table for AL-Sense from Gedeon Richter or some other multi-national company
IBliss acquisition will soon close with positive sales and profits in the millions of dollars making Easton worth $.15 cents a share.
I would say Easton is way undervalued, but not for long.
Easton is way undervalued, but not for long. Here's why
Easton sales have started as they were delivered on the second payment of product by Gedeon Richter for the Gynofit PO.
A deal is on the table from Bayer for VS-Sense which is a product that Bayer is selling in Brazil and Europe.
A deal is on the table for AL-Sense from Gedeon Richter or some other multi-national company
IBliss acquisition will soon close with positive sales and profits in the millions of dollars making Easton worth $.15 cents a share.
I would say Easton is way undervalued, but not for long.
Thanks for the information McKinley. Good to see EAPH is back on the breakout board. It looks like from what I'm hearing, the company is going to retain a full-service investor relations company much better than investor hub. This company does investor relations for small and NASDAQ listed companies. It's good to see that they are trying to do what they can to increase shareholder value and getting market awareness as every company should do for its shareholders. Some of the trolls on here who we all know who they are calling pump and dump. But it's called trying to get the share price up for many reasons most of which is that it's the company's responsibility to increase shareholder value for it shareholders.
The company CEO said that iBliss will definitely close. I'm hoping they do good news on on Monday like they said.
Today's announcement was great. They're going to use that money for good acquisitions that make money. That's on top of the already great news when they have a multibillion-dollar partner selling product for them. Unless the trails to tell you, that partner is called Gedeon Richter. Unless nobody knows, do you have a market cap of €3 billion.
On top of that, they have to order the products which are being sold all around the world. When will those products is sought off dirt and currently sold by Bayer pharmaceuticals. The second product called AmnioSense is very close to having to deal done with Gedeon Richter.